This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Guideline

. 2004 Jul 15:39 Suppl 1:S49-52.

doi: 10.1086/383054.

Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary

Tohru Masaoka¹

Affiliations

PMID: 15250021
DOI: 10.1086/383054

Guideline

Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary

Tohru Masaoka. Clin Infect Dis. 2004.

. 2004 Jul 15:39 Suppl 1:S49-52.

doi: 10.1086/383054.

Author

Tohru Masaoka¹

Affiliation

¹ Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.

PMID: 15250021
DOI: 10.1086/383054

No abstract available

PubMed Disclaimer

Similar articles

Management of the febrile neutropenic patient: a consensus conference.
Picazo JJ. Picazo JJ. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S1-6. doi: 10.1086/383041. Clin Infect Dis. 2004. PMID: 15250013 Review. No abstract available.
Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey.
Yoshida M, Ohno R. Yoshida M, et al. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S11-4. doi: 10.1086/383044. Clin Infect Dis. 2004. PMID: 15250015
Initial empirical antimicrobial therapy: duration and subsequent modifications.
Tamura K. Tamura K. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S59-64. doi: 10.1086/383057. Clin Infect Dis. 2004. PMID: 15250024
The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments.
Rolston KV. Rolston KV. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S44-8. doi: 10.1086/383053. Clin Infect Dis. 2004. PMID: 15250020
[Neutropenia and opportunistic infection].
Ono Y. Ono Y. Nihon Rinsho. 2003 Mar;61 Suppl 3:127-33. Nihon Rinsho. 2003. PMID: 12717959 Review. Japanese. No abstract available.

See all similar articles

Cited by

Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.
Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H. Tanaka A, et al. Antimicrob Agents Chemother. 2014 Aug;58(8):4380-3. doi: 10.1128/AAC.02862-14. Epub 2014 May 19. Antimicrob Agents Chemother. 2014. PMID: 24841261 Free PMC article.
Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim.
Makiguchi T, Odagiri H, Tanaka H, Taima K, Tasaka S. Makiguchi T, et al. Thorac Cancer. 2025 Jun;16(11):e70099. doi: 10.1111/1759-7714.70099. Thorac Cancer. 2025. PMID: 40468685 Free PMC article.
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Takenaka Y, Cho H, Yamamoto M, Nakahara S, Yamamoto Y, Inohara H. Takenaka Y, et al. Support Care Cancer. 2013 Oct;21(10):2861-8. doi: 10.1007/s00520-013-1873-9. Epub 2013 Jun 8. Support Care Cancer. 2013. PMID: 23748486
Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis.
Lan SH, Chang SP, Lai CC, Lu LC, Tang HJ. Lan SH, et al. Medicine (Baltimore). 2020 Feb;99(8):e19321. doi: 10.1097/MD.0000000000019321. Medicine (Baltimore). 2020. PMID: 32080150 Free PMC article.
Involvement of oral bacteria and oral immunity as risk factors for chemotherapy-induced fever with neutropenia in patients with hematological cancer.
Sogawa Y, Fukui M, Nakamura S, Sogabe K, Sumitani R, Yoshioka M, Abe M, Hinode D. Sogawa Y, et al. Int J Hematol. 2020 Dec;112(6):851-859. doi: 10.1007/s12185-020-02975-x. Epub 2020 Sep 3. Int J Hematol. 2020. PMID: 32880823

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information